Non-inferior salvage treatment–free survival at 30 months favored HIFU (90%) versus salvage radical prostatectomy (86%), ...

Dr. Alexander B. Olawaiye speaks on how the ROSELLA trial shows relacorilant plus nab-paclitaxel improves survival in ...

How community oncology prepares for CAR T and gene therapy: safety gains, tech, payer shifts, and 3 must-have capabilities to ...

FDA granted rapid expanded access for daraxonrasib in previously treated metastatic PDAC, reflecting urgency and a ...

The FDA granted regenerative medicine advanced therapy (RMAT) designation to Orca-Q, a second-generation investigational ...

Dr. Evan Wu presents William, a 76-year-old Black man and former smoker (25 pack-year history, quit 15 years ago) who ...

The rapid evolution of advanced therapies like cell and gene therapies is reshaping the oncology landscape and challenging ...

A data monitoring committee recommended stopping FLASH2, a randomized double-blind placebo-controlled confirmatory phase 3 ...

Amandeep Salhotra, MD, of City of Hope National Medical Center in Duarte, California, explores the safety and tolerability of ...

When comprehensive tissue next-generation sequencing (NGS) fails, liquid biopsy should be the reflex strategy, especially in ...

Switching to camizestrant 75 mg while continuing CDK4/6i significantly prolonged PFS to 16.0 vs 9.2 months (HR 0.44; P<.00001 ...

Dr Dulmage highlights that one of the most frequently overlooked early warning signs of clinically significant dermatologic ...